{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:19:40Z","timestamp":1784132380138,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K1643"],"award-info":[{"award-number":["21K1643"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019432","name":"Fujiwara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019432","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-15310-3","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T10:19:55Z","timestamp":1756117195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Circulating galectin-9 as a novel prognosticator in patients with intrahepatic cholangiocarcinoma undergoing surgical resection"],"prefix":"10.1038","volume":"15","author":[{"given":"Makoto","family":"Kurimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Yoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Okura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiko","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Iwaisako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamichi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"15310_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2478\/RAON-2020-0045","volume":"54","author":"I Bartolini","year":"2020","unstructured":"Bartolini, I. et al. Current management of intrahepatic cholangiocarcinoma: From resection to palliative treatments. Radiol Oncol 54, 263\u2013271. https:\/\/doi.org\/10.2478\/RAON-2020-0045 (2020).","journal-title":"Radiol Oncol"},{"key":"15310_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","volume":"401","author":"K Nakachi","year":"2023","unstructured":"Nakachi, K. et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): A multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 401, 195\u2013203. https:\/\/doi.org\/10.1016\/S0140-6736(22)02038-4 (2023).","journal-title":"Lancet"},{"key":"15310_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose, J. N. et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20, 663\u2013673. https:\/\/doi.org\/10.1016\/S1470-2045(18)30915-X (2019).","journal-title":"Lancet Oncol"},{"key":"15310_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/J.SOC.2013.10.004","volume":"23","author":"KM Brown","year":"2014","unstructured":"Brown, K. M., Parmar, A. D. & Geller, D. A. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am 23, 231\u2013246. https:\/\/doi.org\/10.1016\/J.SOC.2013.10.004 (2014).","journal-title":"Surg Oncol Clin N Am"},{"key":"15310_CR5","doi-asserted-by":"publisher","first-page":"101951","DOI":"10.1016\/J.MCP.2024.101951","volume":"73","author":"M Capuozzo","year":"2024","unstructured":"Capuozzo, M. et al. Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments. Mol Cell Probes 73, 101951. https:\/\/doi.org\/10.1016\/J.MCP.2024.101951 (2024).","journal-title":"Mol Cell Probes"},{"key":"15310_CR6","doi-asserted-by":"publisher","first-page":"32344","DOI":"10.1074\/jbc.M109.035196","volume":"284","author":"T Niki","year":"2009","unstructured":"Niki, T. et al. Galectin-9 is a high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex formation. J. Biol. Chem. 284, 32344\u201332352. https:\/\/doi.org\/10.1074\/jbc.M109.035196 (2009).","journal-title":"J. Biol. Chem."},{"key":"15310_CR7","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/J.GENDIS.2022.05.020","volume":"10","author":"Y Lv","year":"2022","unstructured":"Lv, Y., Ma, X., Ma, Y., Du, Y. & Feng, J. A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9). Genes Dis 10, 2366\u20132382. https:\/\/doi.org\/10.1016\/J.GENDIS.2022.05.020 (2022).","journal-title":"Genes Dis"},{"key":"15310_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/J.BBCAN.2013.04.006","volume":"1836","author":"R Heusschen","year":"2013","unstructured":"Heusschen, R., Griffioen, A. W. & Thijssen, V. L. Galectin-9 in tumor biology: A jack of multiple trades. Biochim Biophys Acta 1836, 177\u2013185. https:\/\/doi.org\/10.1016\/J.BBCAN.2013.04.006 (2013).","journal-title":"Biochim Biophys Acta"},{"key":"15310_CR9","doi-asserted-by":"publisher","first-page":"9921","DOI":"10.1038\/S41467-021-21099-2","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang, R. et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun 12, 9921. https:\/\/doi.org\/10.1038\/S41467-021-21099-2 (2021).","journal-title":"Nat Commun"},{"key":"15310_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2174\/1872214811307020006","volume":"7","author":"S Fujihara","year":"2013","unstructured":"Fujihara, S. et al. Galectin-9 in cancer therapy. Recent Pat Endocr Metab Immune Drug Discov 7, 130\u2013137. https:\/\/doi.org\/10.2174\/1872214811307020006 (2013).","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"15310_CR11","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1159\/000487294","volume":"45","author":"K Wang","year":"2018","unstructured":"Wang, K. et al. Prognostic role of high gal-9 expression in solid tumours: A meta-analysis. Cell Physiol Biochem 45, 993\u20131002. https:\/\/doi.org\/10.1159\/000487294 (2018).","journal-title":"Cell Physiol Biochem"},{"key":"15310_CR12","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/S41598-017-13802-5","volume":"7","author":"M Labrie","year":"2017","unstructured":"Labrie, M., De Araujo, L. O. F., Communal, L., Mes-Masson, A. M. & St-Pierre, Y. Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers. Sci Rep 7, 802. https:\/\/doi.org\/10.1038\/S41598-017-13802-5 (2017).","journal-title":"Sci Rep"},{"key":"15310_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/S41598-019-47235-Z","volume":"9","author":"K Sideras","year":"2019","unstructured":"Sideras, K. et al. Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. Sci Rep 9, 235. https:\/\/doi.org\/10.1038\/S41598-019-47235-Z (2019).","journal-title":"Sci Rep"},{"key":"15310_CR14","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1038\/S41388-020-1186-7","volume":"39","author":"AM Seifert","year":"2020","unstructured":"Seifert, A. M. et al. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels. Oncogene 39, 3102\u20133113. https:\/\/doi.org\/10.1038\/S41388-020-1186-7 (2020).","journal-title":"Oncogene"},{"key":"15310_CR15","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3390\/CANCERS13194819","volume":"13","author":"BB Blair","year":"2021","unstructured":"Blair, B. B. et al. Increased circulating levels of galectin proteins in patients with breast, colon, and lung cancer. Cancers (Basel) 13, 819. https:\/\/doi.org\/10.3390\/CANCERS13194819 (2021).","journal-title":"Cancers (Basel)"},{"key":"15310_CR16","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2147\/OTT.S378933","volume":"15","author":"T Reyes-Vallejo","year":"2022","unstructured":"Reyes-Vallejo, T. et al. Serum levels of galectin-9 are increased in cervical cancer patients and are higher in advanced clinical stages. Onco Targets Ther 15, 1211\u20131220. https:\/\/doi.org\/10.2147\/OTT.S378933 (2022).","journal-title":"Onco Targets Ther"},{"key":"15310_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/JSO.27758","author":"GVM de Filho","year":"2024","unstructured":"de Filho, G. V. M., Costa, G. J., Martins, M. R. & Torres, L. C. Circulating levels of galectin-9 are a potential biomarker of survival in advanced non-small-cell lung cancer. J Surg Oncol https:\/\/doi.org\/10.1002\/JSO.27758 (2024).","journal-title":"J Surg Oncol"},{"key":"15310_CR18","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1245\/S10434-017-6025-X","volume":"25","author":"YS Chun","year":"2018","unstructured":"Chun, Y. S., Pawlik, T. M. & Vauthey, J. N. 8th edition of the AJCC cancer staging manual: Pancreas and hepatobiliary cancers. Ann Surg Oncol 25, 845\u2013847. https:\/\/doi.org\/10.1245\/S10434-017-6025-X (2018).","journal-title":"Ann Surg Oncol"},{"key":"15310_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0B013E3181B13CA2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien, P. A. et al. The Clavien-Dindo classification of surgical complications: Five-year experience. Ann Surg 250, 187\u2013196. https:\/\/doi.org\/10.1097\/SLA.0B013E3181B13CA2 (2009).","journal-title":"Ann Surg"},{"key":"15310_CR20","volume-title":"Applied statistics for the behavioral sciences","author":"DE Hinkle","year":"2003","unstructured":"Hinkle, D. E., Wiersma, W. & Jurs, S. G. Applied statistics for the behavioral sciences 5th edn. (Massachusetts, Houghton Mifflin, 2003).","edition":"5"},{"key":"15310_CR21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1159\/000449339","volume":"5","author":"T Yoh","year":"2016","unstructured":"Yoh, T. et al. Is surgical resection justified for advanced intrahepatic cholangiocarcinoma?. Liver Cancer 5, 280\u2013289. https:\/\/doi.org\/10.1159\/000449339 (2016).","journal-title":"Liver Cancer"},{"key":"15310_CR22","doi-asserted-by":"publisher","first-page":"104287","DOI":"10.1016\/J.CELLIMM.2021.104287","volume":"361","author":"P Moar","year":"2021","unstructured":"Moar, P. & Tandon, R. Galectin-9 as a biomarker of disease severity. Cell Immunol 361, 104287. https:\/\/doi.org\/10.1016\/J.CELLIMM.2021.104287 (2021).","journal-title":"Cell Immunol"},{"key":"15310_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/CARCIN\/BGAD094","volume":"45","author":"Y Hori","year":"2024","unstructured":"Hori, Y. et al. Ferroptosis-related gene glutathione peroxidase 4 promotes reprogramming of glucose metabolism via Akt\u2013mTOR axis in intrahepatic cholangiocarcinoma. Carcinogenesis 45, 119\u2013130. https:\/\/doi.org\/10.1093\/CARCIN\/BGAD094 (2024).","journal-title":"Carcinogenesis"},{"key":"15310_CR24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1078-0432.CCR-18-0124","volume":"25","author":"T Yoh","year":"2019","unstructured":"Yoh, T. et al. Serum nardilysin, a surrogate marker for epithelial\u2013mesenchymal transition, predicts prognosis of intrahepatic cholangiocarcinoma after surgical resection. Clin. Cancer Res. 25, 619\u2013628. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0124 (2019).","journal-title":"Clin. Cancer Res."},{"key":"15310_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/EVIDOA2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh, D.-Y. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence 1, 15. https:\/\/doi.org\/10.1056\/EVIDOA2200015 (2022).","journal-title":"NEJM Evidence"},{"key":"15310_CR26","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1853\u20131865. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4 (2023).","journal-title":"Lancet"},{"key":"15310_CR27","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1186\/S12957-020-02082-5","volume":"18","author":"L Tian","year":"2020","unstructured":"Tian, L. et al. PD-1\/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome. World J Surg Oncol 18, 825. https:\/\/doi.org\/10.1186\/S12957-020-02082-5 (2020).","journal-title":"World J Surg Oncol"},{"key":"15310_CR28","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1245\/S10434-016-5708-Z","volume":"24","author":"T Yoh","year":"2017","unstructured":"Yoh, T. et al. A novel biomarker-based preoperative prognostic grading system for predicting survival after surgery for intrahepatic cholangiocarcinoma. Ann Surg Oncol 24, 1351\u20131357. https:\/\/doi.org\/10.1245\/S10434-016-5708-Z (2017).","journal-title":"Ann Surg Oncol"},{"key":"15310_CR29","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1136\/JITC-2022-005714","volume":"11","author":"S Schlichtner","year":"2023","unstructured":"Schlichtner, S. et al. T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint proteins. J Immunother Cancer 11, 714. https:\/\/doi.org\/10.1136\/JITC-2022-005714 (2023).","journal-title":"J Immunother Cancer"},{"key":"15310_CR30","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.18632\/AGING.203909","volume":"14","author":"J Jiao","year":"2022","unstructured":"Jiao, J. et al. Galectin-9 expression predicts poor prognosis in hepatitis B virus-associated hepatocellular carcinoma. Aging 14, 1879\u201390. https:\/\/doi.org\/10.18632\/AGING.203909 (2022).","journal-title":"Aging"},{"key":"15310_CR31","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/S00268-019-04917-Z","volume":"43","author":"T Yoh","year":"2019","unstructured":"Yoh, T. et al. Reappraisal of prognostic impact of tumor SUVmax by 18F-FDG-PET\/CT in intrahepatic cholangiocarcinoma. World J Surg 43, 1323\u20131331. https:\/\/doi.org\/10.1007\/S00268-019-04917-Z (2019).","journal-title":"World J Surg"},{"key":"15310_CR32","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/NCB3330","volume":"18","author":"EL LaGory","year":"2016","unstructured":"LaGory, E. L. & Giaccia, A. J. The ever-expanding role of HIF in tumour and stromal biology. Nat Cell Biol 18, 356\u2013365. https:\/\/doi.org\/10.1038\/NCB3330 (2016).","journal-title":"Nat Cell Biol"},{"key":"15310_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1186\/S12967-025-06583-3","volume":"23","author":"S Bakrim","year":"2025","unstructured":"Bakrim, S. et al. Targeting inflammation in cancer therapy: From mechanistic insights to emerging therapeutic approaches. J Transl Med 23, 583. https:\/\/doi.org\/10.1186\/S12967-025-06583-3 (2025).","journal-title":"J Transl Med"},{"key":"15310_CR34","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/JAMASURG.2013.5137","volume":"149","author":"MN Mavros","year":"2014","unstructured":"Mavros, M. N., Economopoulos, K. P., Alexiou, V. G. & Pawlik, T. M. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: Systematic review and meta-analysis. JAMA Surg 149, 565\u2013574. https:\/\/doi.org\/10.1001\/JAMASURG.2013.5137 (2014).","journal-title":"JAMA Surg"},{"key":"15310_CR35","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1186\/S12876-018-0912-X","volume":"18","author":"KM Chan","year":"2018","unstructured":"Chan, K. M. et al. Characterization of intrahepatic cholangiocarcinoma after curative resection: Outcome, prognostic factor, and recurrence. BMC Gastroenterol 18, 912. https:\/\/doi.org\/10.1186\/S12876-018-0912-X (2018).","journal-title":"BMC Gastroenterol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15310-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15310-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15310-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T23:04:18Z","timestamp":1756508658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15310-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15310"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-15310-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Opt-out informed consent was obtained to use the participant data for research. Informed consent was obtained from all participants and\/or their legal guardians. This study was approved by the Ethics Committee of Kyoto University Hospital, Graduate School and Faculty of Medicine (Approval No. R3844), and performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31229"}}